Medovex Corporation's Streamline IV Suspension System Featured at HospiMedica.com

ATLANTA, GA--(Marketwired - Oct 28, 2015) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that on October 25, HospaMedica.com featured the Company's Streamline® IV Suspension System ("ISS"). The article may be found at the following link: "IV Suspension System Simplifies Intra-Hospital Transport."

"According to Critical Care Medicine, there are roughly 100,000 critical care beds in US hospitals. Streamline's ISS technology serves a growing need for safety and efficiency for both patients and caregivers in the hospital setting," said Jarrett Gorlin, CEO of Medovex. "The product provides caregivers with a more efficient means of handling the growing amount of patient equipment that remains with patients as they move about a hospital."

The ISS is a unique and effective solution available for managing cumbersome IV poles with mounted IV infusion pumps or other equipment at the bedside and during intra-hospital patient transports. The Streamline ISS provides an easy-to-use technology platform that mounts the ISS to beds or stretchers in the hospital or other care facility.

New efficiencies benefit patients by reducing the risk and associated costs of workplace injuries and the time for transferring patients and equipment. In seconds the ISS can go from an infusion stand to a suspended, securely locked part of beds or stretchers.

Medovex's Streamline with ISS technology serves a growing need for both patients and caregivers in the hospital setting. The product provides caregivers with an efficient means of handling the growing amount of patient equipment that remains with patients as they move about a hospital.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground- breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is currently in development and is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.